Wells Fargo & Company MN Sells 31,773 Shares of Hologic, Inc. (NASDAQ:HOLX)

Wells Fargo & Company MN cut its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 7.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 369,397 shares of the medical equipment provider's stock after selling 31,773 shares during the quarter. Wells Fargo & Company MN owned 0.16% of Hologic worth $26,630,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Norges Bank acquired a new stake in shares of Hologic during the 4th quarter valued at approximately $133,414,000. Boston Partners grew its position in shares of Hologic by 81.0% in the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock valued at $257,959,000 after purchasing an additional 1,602,463 shares during the last quarter. Nordea Investment Management AB increased its stake in shares of Hologic by 32.7% during the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider's stock worth $159,911,000 after purchasing an additional 544,889 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Hologic in the 4th quarter valued at approximately $27,007,000. Finally, Arrowstreet Capital Limited Partnership increased its position in Hologic by 27.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,687,347 shares of the medical equipment provider's stock worth $121,641,000 after purchasing an additional 361,539 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Hologic Stock Up 1.2 %

Shares of HOLX traded up $0.70 during mid-day trading on Thursday, hitting $57.20. 832,859 shares of the company's stock were exchanged, compared to its average volume of 1,925,276. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The stock has a market cap of $12.83 billion, a price-to-earnings ratio of 18.05, a P/E/G ratio of 2.14 and a beta of 0.82. Hologic, Inc. has a twelve month low of $56.00 and a twelve month high of $84.67. The firm has a fifty day moving average of $61.87 and a two-hundred day moving average of $71.15.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on HOLX shares. Stephens reiterated an "overweight" rating and set a $84.00 target price on shares of Hologic in a report on Thursday, February 6th. William Blair reiterated an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Citigroup dropped their price target on Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Evercore ISI dropped their target price on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a report on Thursday, February 6th. Finally, Royal Bank of Canada lowered their price objective on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a research report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.